Certain Prostate Cancer Patients May Benefit From Higher Radiation Doses in Fewer Sessions, Study Shows

Certain Prostate Cancer Patients May Benefit From Higher Radiation Doses in Fewer Sessions, Study Shows
Stereotactic body radiation therapy (SBRT) — a kind of radiation therapy that delivers high doses of radiation over a shorter treatment course — is as safe and effective as the traditional external beam radiation therapy (EBRT) for patients with low- and intermediate-risk prostate cancer, according to a long-term study. The study, "Long-Term Outcomes of Stereotactic Body Radiation Therapy for Low and Intermediate-Risk Prostate Adenocarcinoma: A Multi-Institutional Consortium Study," was presented at the American Society for Radiation Oncology (ASTRO) 2018 Annual Meeting, held recently in San Antonio. Radiation therapy is a good alternative for patients with early-stage prostate cancer that has not migrated to other organs or adjacent tissues. However, the standard treatment course takes up to nine weeks with five treatments every week. SBRT offers a significantly shorter treatment course, with fewer radiotherapy sessions, by increasing the radiation dosage and focusing on the tumor site to avoid adjacent tissue. SBRT has been around for decades, but concerns associated with the long-term safety of receiving high doses of radiation therapy and a lack of studies that address these issues have prevented it from becoming more widely used. To solve this problem, researchers conducted a multi-institutional study to evaluate the long-term outcomes associated with this therapy in prostate cancer patients. The study includes data from 10 institutional trials and two large multi-institutional studies. It examined the long-term safety and efficacy of SBRT in 2,142 men with low- and intermediate-risk prostate cancer who were enrolled in institutional Phase 2 trials of SBRT from 2000 to 2012. "Radiation therapy is typically delivered in small daily dose
Subscribe or to access all post and page content.